Old Web
English
Sign In
Acemap
>
authorDetail
>
Anna Koroleva
Anna Koroleva
Novo Nordisk
Medicine
Semaglutide
Obesity
Overweight
Weight loss
4
Papers
61
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1)
2021
Journal of the Endocrine Society
Robert F. Kushner
W. Timothy Garvey
Dan Hesse
Anna Koroleva
Soo Lim
Ildiko Lingvay
Ofri Mosenzon
Signe O. R. Wallenstein
Thomas A. Wadden
Carel W. le Roux
Show All
Source
Cite
Save
Citations (0)
Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4)
2021
Journal of the Endocrine Society
Ofri Mosenzon
W. Timothy Garvey
Dan Hesse
Anna Koroleva
Robert F. Kushner
Soo Lim
Ildiko Lingvay
Signe O. R. Wallenstein
Thomas A. Wadden
Carel W. le Roux
Show All
Source
Cite
Save
Citations (1)
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
2021
JAMA
Thomas A. Wadden
Timothy S. Bailey
Liana K. Billings
Melanie J. Davies
Juan P. Frias
Anna Koroleva
Ildiko Lingvay
Patrick M. ONeil
Domenica Rubino
Dorthe Skovgaard
Signe O. R. Wallenstein
W. Timothy Garvey
Step Investigators
Show All
Source
Cite
Save
Citations (59)
4 Semaglutide 2.4 mg and Intensive Behavioral Therapy in Subjects With Overweight or Obesity (STEP 3)
2021
Thomas A. Wadden
Timothy S. Bailey
Liana K. Billings
Juan P. Frias
Anna Koroleva
René Gollan
Patrick M. ONeil
Domenica Rubino
Dorothe Skovgaard
Signe O. R. Wallenstein
Timothy Garvey
Show All
Source
Cite
Save
Citations (1)
1